Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers significant potential advantages.
Click here to learn more about this ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus’ proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, which does not require any reconstitution or conditioning before administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently self-administered.
If you live in the US, you can visit this website expressly set up for US patients with information on the trials.
The two links below will take you to the trials:
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
A word about Camurus:
Camurus is committed to developing and commercializing innovative and long-acting medicines to treat severe and chronic conditions, including opioid dependence, pain, cancer, and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies to deliver improved quality of life, treatment outcomes, and resource utilization.
Editors note: We encourage our readers to learn more and participate in clinical trials as a way to help all patients. We do not endorse or recommend participation in any specific clinical trials or studies.
© 2021 – 2022, Pituitary World News. All rights reserved.